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S U M M A R Y
B A C K G R O U N D : Despite a scarcity of tuberculosis (TB)
cost data, a substantial body of evidence has been
accumulating for drug-susceptible TB (DS-TB) treat-
ment. In this study, we review unit costs for DS-TB
treatment from a provider’s perspective. We also
examine factors driving cost variations and extrapolate
unit costs across low- and middle-income countries
(LMICs).
M E T H O D S : We searched published and grey literature
for any empirically collected TB cost estimates. We
selected a subgroup of estimates looking at DS-TB
treatment. We extracted information on activities and
inputs included. We standardised costs into an average
per person-month, fitted a multi-level regression model
and cross-validated country-level predictions. We then
extrapolated estimates for facility-based, directly ob-
served DS-TB treatment across countries.
R E S U LT S : We included 95 cost estimates from 28
studies across 17 countries. Costs predictions were
sensitive to characteristics such as delivery mode,
whether hospitalisation was included, and inputs ac-
counted for, as well as gross domestic product per capita.
Extrapolation results are presented with uncertainty
intervals (UIs) for LMICs. Predicted median costs per 6
months of treatment were US$315.30 (95% CI
US$222.60–US$417.20) for low-income, US$527.10
(95% CI US$395.70–US$743.70) for lower middle-
income and US$896.40 (95% CI US$654.00–
US$1214.40) for upper middle-income countries.
C O N C L U S I O N S : Our study provides country-level DS-
TB treatment cost estimates suitable for priority setting.
These estimates, while not standing as a substitute for
local high-quality primary data, can inform global,
regional and national exercises.
K E Y W O R D S : cost; tuberculosis; first-line treatment;
LMIC; systematic review
IN 2017, APPROXIMATELY 10 million people
developed tuberculosis (TB), with an estimated 1.9
million deaths due to TB globally.1 To accelerate
progress in reducing this TB burden, the World
Health Organization (WHO) has set targets of 95%
reduction in TB deaths compared to 2015 rates, and
90% reduction in TB incidence rates to less than 10
TB cases per 100 000 population by 2035.2 Achieving
these targets will require a scale-up of current
services, as well as the introduction of new technol-
ogies.3 These expansions to national TB programmes
will stretch current TB budgets.2 Estimates of costs of
healthcare provision are a key component of eco-
nomic evaluations, budgeting and planning when
considering the introduction of new technologies or
the expansion of interventions and services. However,
cost data for TB services and interventions available
globally remains scarce and a concern to analysts and
policy makers alike.2
The Global Health Cost Consortium (GHCC) was
established to improve the quality and availability of
costs estimates for HIV and TB, with two main
products. The first product is a comprehensive unit
cost study repository (UCSR) summarising and
standardising existing cost data from a systematic
review of all literature to date in HIV and TB.4 The
second product is a reference case to improve
methods and reporting of costing studies for estimat-
ing the costs of global health services and interven-
tions.5
For TB, in addition to this updated effort by
GHCC, 10 systematic reviews have been published
addressing different aspects of cost data. Four
systematic reviews summarised evidence on patient-
incurred costs in various settings,6–9 stressing the
elevated financial burden and risk faced by TB
patients and their households. From a provider
perspective, there have been seven systematic reviews.
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These reviews covered various aspects of service
delivery: treatment costs for drug-susceptible and
multidrug-resistant TB for centralised and decentral-
ised services;6,10,11 costs of diagnostic and monitoring
tests and algorithms;12,13 and costs of TB-related
services when patients are co-infected with HIV.14,15
The studies converge in concluding that there is a
scarcity of data and a need for standardisation of
costing methods going forward.
The aim of the present study is to examine the
current evidence base on TB costs to explore whether
it could be used to estimate costs in countries with
data scarcity. We reviewed and standardised unit
costs for treatment of drug-susceptible TB from a
provider’s perspective where a substantial body of
evidence has been accumulating. We examined the
factors driving cost variation and then assessed the
extent to which TB cost data currently available can
be used to estimate unit costs across low- and middle-
income countries (LMICs).
METHODS
This systematic review was conducted and is reported
following the principles of the PRISMA statement,16
provided in the Supplementary Data (Supplementary
Table S1). There was no protocol published for this
analysis; however, the methods for the development
of the Unit Cost Study Repository (UCSR), the basis
of data included, covering searches, article selection,
and data extraction, are presented in detail else-
where.17
Ethical approval was not required for this study, as
it pertains to secondary data analysis only.
Search strategy, selection of studies and
standardisation of cost estimates
Our search and article selection process included
three steps. First, we searched the UCSR.4 Briefly, for
TB-related costs, a systematic search of the published
literature in PubMed, EMBASE, EconLit, Cochrane,
National Health Service Economic Evaluation Data-
base; and the Cost-Effectiveness Analysis Registry
was done in July 2016 using broad searches,
including economic terms (e.g., ‘cost’, ‘economic’ or
‘financial’), disease-related terms (e.g., ‘TB’, ‘tuber-
culosis, ‘MDR’, ‘XDR’) and intervention-specific
keywords (e.g., ‘treatment’, ‘DOTS’, ‘isoniazid pre-
ventive therapy’, ‘patient cost’). These searches were
then updated to include two additional databases,
Web of Science and Literatura Latinoamericana en
Ciencias de la Salud (LILACS) in March 2017. There
were no exclusions based on language or intervention
type. Grey literature, experts in the field and the
reference lists of previous systematic reviews were
also consulted. All studies presenting empirically
collected TB cost data from a provider or patient
perspective in low, lower-middle and upper middle-
income countries covering the period from January
1990 to March 2017 were included in the UCSR.
Second, we updated the UCSR searches in February
2019 and retrieved all studies presenting empirically
collected TB cost data from a provider or patient
perspective in LMICs covering the period from
March 2017 to February 2019 using the same
searches and inclusion criteria. Finally, from all the
studies retrieved, we selected a subset of studies
presenting cost data from a provider perspective
published since 2000 for drug-susceptible TB treat-
ment. We also restricted this review to those studies
presenting TB treatment using a standard 6-month
rifampicin-containing regimen, i.e., 2-month inten-
sive phase including isoniazid, rifampicin, pyrazin-
amide and ethambutol, followed by a 4-month
continuation phase of isoniazid and rifampicin only.
Two authors screened all articles retrieved and
verified eligibility of those included in the review.
From the studies included, we extracted information
describing the study setting and costing method such
as country, intervention description, including service
delivery characteristics, the year when the authors
reported data being analysed and targeted popula-
tion. We also extracted data describing the cost inputs
included in the unit cost estimates to assess the risk of
bias in individual estimates. The primary outcome of
interest was unit costs, defined as cost per person
treated for the full duration of the treatment,
including both the intensive and continuation phases.
We converted all cost estimates into United States
dollars ($US) using the exchange rate for the year of
the study, then standardised them into 2017 $US
using US gross domestic product (GDP) price
deflator. Finally, we calculated an average cost per
person-month of treatment by dividing the episode
cost by 6 months’ treatment duration.
Data analysis
We tested eight random effects multi-level regression
models (specifications can be found in Supplementary
Table S2). Covariates were defined at two levels:
country-level and study-level. The following country-
level variables were included in our analysis: TB case
detection rate18 (now treatment coverage) and HIV
prevalence19 (for the year when the authors reported
data being analysed in each study) as indicators of
local burden and programme size and performance
for TB and local burden for HIV; antiretroviral
treatment (ART) coverage in 2017, as opposed to
year-specific coverage for two reasons: 1) it represents
an indicator of local investments in vertical pro-
grammes and 2) data for studies before year 2005
were patchy. Finally, we added GDP per capita20 (for
the year when the authors reported data being
analysed in each study) as often associated with
health service cost variation. Second-order terms for
HIV prevalence and antiretroviral therapy (ART)
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coverage were also tested in the models to normalise
these variables, as the relationship between HIV
prevalence/ART coverage and mean cost was found
to shift from linear to quadratic after a certain point.
We included four variables related to the character-
istics of the unit cost estimate describing service
delivery modalities that are relevant to treatment cost
variation. The first variable indicated whether hospi-
talisation costs were included. Hospitalisation costs
come from hospitalisation being recommended as
part of the treatment. The second variable is related
to whether the TB treatment strategy followed was
directly observed treatment (DOT), self-reported by
authors. The third variable relates to the inputs
included in the cost estimate, for example, whether or
not capital costs had been included in the estimate
presented. The final variable indicated the location of
treatment delivery, whether facility-based or commu-
nity-based. The Bayesian information criterion (BIC)
and the Akaike information criterion (AIC) were
estimated to select the model with the best fit. Lower
values of BIC or AIC indicate a better fit for the
model.
Our selected model was specified as follows:
log costð Þiy ¼ aþ b1TBcdry þ b2 log GDPpcð Þy
þ b3HIVy þ b4HOSPi þ b5NDOTi
þ b6COMMi þ b7INPUTi þ uiy
þ eiy
where
 cost is the average unit cost (per person-month of
treatment) in 2017 $US, log-transformed to ac-
count for a right-skewed distribution;
 i¼ (1, . . ., I) refers to the individual studies
 y¼ (1, . . ., Y) refers to year of data-country pairs
 TBcdr is the TB case detection rate. It is expressed
as a proportion to reflect the number of new and
relapsed TB cases notified to the WHO divided by
the estimated number of incident TB cases in a
given year and country. All data were collated
based on the year when the authors reported data
being collected or analysed in each study or, if not
this was not available, year of publication (y).
 GDPpc is the GDP divided by mid-year popula-
tion20 to produce GDP per capita in current $US.
All data were reported based on the year when the
authors reported data being analysed in each study
(y).
 HIV is the HIV prevalence among adults (15–49
years) as a proportion. All data were reported
based on the year when the authors reported data
being analysed in each study (y).
 HOSP is a variable for inclusion of hospitalisation
costs for each study. It is equal to 1 if hospitalisa-
tion costs have been included in the estimates.
 NDOT is a dummy variable to indicate the
treatment modality for each study. It is equal to 1
for non-DOT.
 COMM is a variable indicating the location of
service delivery for each study. It is equal to 1 if the
treatment is delivered in the community.
 INPUT is a dummy variable to indicate whether the
authors included all key inputs in their estimate
(i.e., capital, personnel and recurrent costs)
 uiy is the between-study error, eiy is the within-study
error.
We first tested for heterogeneity using a Hausman
test and determined that a random effects model was
appropriate. We employed the xtreg and xtmixed
commands in STATA (StataCorp, College Station,
TX, USA) using random effects and maximum
likelihood estimation to fit a random intercept model,
but we opted to use the xtmixed for further prediction
as more appropriate due to the nature of our data
sources: 1) studies performed in a variety of countries
and time points; and 2) different settings and delivery
of interventions in each study. In the Supplementary
Data, we provide a visual representation of the
observed vs. the predicted values using the best-fit
model that indicates that the xtmixed approach
provided a better fit and estimates than the xtreg
approach (Supplementary Figure S1).
To check the predictive validity of our model, we
could either remove single data points and check the
prediction from the model fit to the rest of the data or
we could remove all data points for each country and
use the data from the remaining countries to do the
same prediction. We chose the second cross-valida-
tion check of the predictive accuracy of the selected
model because our aim was to predict across
countries. After cross-validation checks, we then used
our best fit model and local covariates to predict
median cost per person-month of first line TB
treatment using DOT, including all inputs (i.e.,
capital, personnel and recurrent costs) without
hospitalisation as the most common delivery option,
and the one providing the best predictive power
across LMICs.
RESULTS
Of the 17 312 studies identified after duplications
were removed, we assessed abstracts and full texts
from 843 studies (six articles were not reviewed as we
did not have access to the full text21–26). Of the 205
studies presenting empirically collected TB cost data,
we excluded 80 articles reporting only costs incurred
by patients and their households. A total of 96 studies
reported costs from a provider perspective for
interventions and services other than first-line stan-
dardised treatment for drug-susceptible TB and were
also excluded. In total, 29 studies published between
2000 and 2018 contributing 106 unit costs across 19
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countries were eligible for inclusion (Figure 1). Unit
costs from China and Syria were then excluded in the
complete dataset for analysis, as there was no
information available for HIV prevalence for the
year when the authors reported data in these two
countries. Our final dataset included 28 studies from
17 countries and reported a total of 95 unit costs.27–54
These estimates (as well as all other TB unit costs for
different interventions) can be found online by
country in the UCSR of the Global Health Cost
Repository (available from: https://ghcosting.org/
pages/data/ucsr/app/).
In Supplementary Table S3, we describe character-
istics from the studies included and in Supplementary
Table S4, we present the characteristics of the unit
costs. Unit cost availability is not uniformly distributed
across countries – some countries, like South Afri-
ca,28,36,48,49 have more information available than
others (Figure 2). Most studies estimated costs under a
DOT strategy either facility-based (n ¼ 25) or
community-based (n ¼ 15). In addition to six studies
disaggregating costs by smear status of the patient,
another six studies restricted the population studied to
smear-positive patients.28,29,34,35,38,39,41,45,47,49,51,53
Two additional costing studies took place alongside
the trials.31,45 Costing methods and allocation ap-
proaches of shared resources varied between studies.
While most studies reported cost estimates, including
all relevant costs inputs (capital, personnel and
recurrent costs), six studies excluded some aspects of
capital costs.34,38,40.43,46,53 Variation was found in the
activities included and the valuation decisions when
accounting for the time of community health workers/
volunteers. Variation was also observed in the
inclusion of diagnosis, treatment and management of
adverse drug events and hospitalisations. Only one
study excluded all laboratory costs (diagnosis and
monitoring)2,7 while another included diagnosis as
part of the treatment unit cost reported.41 Two studies
reported treatment for adverse drug reactions.49,54
Overall larger variation in the inclusion of hospital-
isation costs was observed. In some settings, hospital-
isation was recommended as part of the standard of
care evaluated, like in the Russian Federation, and
represented a high proportion of the costs.33,35,36,41,52
In other settings, hospitalisation was not a require-
ment, but its costs were included if patients needed to
be hospitalised during their treatment. Finally, most
unit costs were reported as cost per patient treated,
except for four papers looking at cost per patient
completing treatment28,44,50,52 and one study report-
ing costs per patient successfully treated.45 Looking at
the distribution of unit costs (Figure 3), studies that
included hospitalisation costs and facility-based ser-
vice delivery had higher unit costs compared to those
not including hospitalisation costs or community-
based service delivery.
Our next step was to examine the potential drivers
of unit costs within a regression framework. We ran
various models, presented in Supplementary Table
S1. The best fitted model is presented in the Table.
Our model results show a statistically significant
positive association between unit cost and GDP per
capita, all inputs included and hospitalisation, while
community-based services are negatively associated
with unit costs (Table). The coefficients presented can
Figure 1 Search results and article selection. CEA¼ cost-effectiveness analysis; TB¼ tuberculosis; NHS¼National Health Service;
EED¼ Economic Evaluation Database; LILACS¼ Literatura Latinoamericana en Ciencias de la Salud; TB¼ tuberculosis.
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be interpreted, for example, as a 1% increase in TB
case detection rate being associated with a statisti-
cally non-significant 0.2% increase in average unit
cost per person-month of treatment, whereas a 1%
increase in GDP per capita per year was associated
with a statistically significant 0.44% increase in
average unit cost per person-month of treatment.
We found a high correlation (r ¼ 0.92) between
observed and predicted values for the selected model
(Figure 4).
In the Supplementary Data (Supplementary Figure
S2), we present the validation results for the prediction
model. We observed a variation in performance by
setting. The model performs better in settings with
facility-based DOT costs for drug-susceptible TB
without hospitalisation than in those settings where
hospitalisation is included or where service delivery
happens in the community. Finally, in Supplementary
Table S5, we present a table with predicted unit costs
with 95% confidence intervals for all LMICs. Our
predicted median costs per 6 months of treatment are
for low-income (US$315.30, 95% CI US $222.60–
US$417.20), lower middle-income (US$527.10, 95%
CI US $395.70–US$743.70) and upper middle-income
(US$896.40, 95% CI US $654.00–US$1214.40) coun-
tries.
DISCUSSION
This review provides an up-to-date overview of
primary data available for first-line treatment of
drug-susceptible TB in LMICs. We also put forward a
multi-level regression analysis of standardised costs
to model and extrapolated to other countries without
data, controlling for epidemiological and socio-
economic differences between settings and service
delivery.
We found that unit costs for drug-susceptible TB
treatment were positively associated with GDP per
capita, inputs included and hospitalisation, while
community-based services were negatively associat-
ed. Our prediction model performed well for facility-
based DOT costs for drug-susceptible TB without
hospitalisation; however, it performed worse in those
settings where hospitalisation is included or where
service delivery happens in the community. This may
be due to variations in hospitalisation duration and/
or procedures that patients underwent during hospi-
talisation, and secondly, due to the variations in the
valuation of community health workers or volunteers
time.
This study improves previous models in that it
accounts for within- and between-study variance
using a multi-level approach to regression for
extrapolation in facility-based DOT costs. When
comparing our median predicted cost per 6 months of
treatment for low-income (US$315.30), lower mid-
dle-income (US$527.10) and upper middle-income
(US$896.40) countries with previously published
estimates (US$258.00, US$273.00, US$840.00, re-
spectively),6 we predict higher overall medians, with
the difference becoming smaller as income increases.
This may be because we are predicting only complete
estimates for a 6-month duration in facility-based
DOT service delivery models without hospitalisation
and the previous systematic review did not control for
the impact of predicting estimates for full duration,
hospitalisation policy or inputs included in the cost
Figure 2 Availability of unit costs by country for the treatment of drug-susceptible tuberculosis.
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estimates. We also present uncertainty around our
extrapolated estimates, which helps contextualise the
quality of the data available informing these predict-
ed values.
There are some limitations in this study. First, we
limited the analysis to first-line treatment costs from a
health service perspective. These estimates are pre-
sented aggregated. If disaggregated by HIV status, the
predictions will allow for more granularity in priori-
tisation exercises. However, we were not able to
expand the analysis in such way with the data
currently available (for more information on the
literature available on HIV-TB costs, we refer to de
Siqueira-Filha et al.14). Overall, there is an urgent need
to expand this analysis to other services and interven-
tions in TB, such as treatment for drug-resistant TB,
diagnosis and prevention. TB patients tend to face
substantial costs that were not included. Second, we
did not include variables known to be important
drivers of costs in the model specifications—such as
scale. This is because the data available did not provide
enough detail to allow for this. In the future, a more
detailed specification and appropriate standardisation
of units will allow for more precision in the
predictions. Finally, there is an important uncertainty
reflected in the width of confidence intervals of our
estimates; while the estimates will be useful in
informing cost-effectiveness analyses, they may lack
the precision needed for budgeting and planning
purposes.
Our study confirms that TB treatment for drug-
susceptible TB is a low-cost intervention in most
Table Multilevel regression model results (95 data points)
Variables
Descriptive statistics Model results
n (%) b (95%CI) P value
TB case detection rate* at year y,† mean 6 SD 64.1 6 24.8 0.002 (0.007 to 0.011) 0.658
Log (GDP per capita at year y†), $US, mean 6 SD 2961.1 6 3 247.3‡ 0.444 (0.226 to 0.662) ,0.001§
HIV prevalence at year y†, %, mean 6 SD 4.7 6 8.2 0.016 (0.011 to 0.043) 0.247
Includes hospital costs, yes 36 (40.5) 0.460 (0.168 to 0.751) 0.002§
DOTS, no 24 (26.9) 0.283 (0.573 to 0.007) 0.056
Community-based (reference: facility-based) 27 (28.4) 0.401 (0.691 to 0.111) 0.007§
Included all key input cost, yes 72 (75.8) 1.571 (1.005 to 2.137) ,0.001§
Constant 0.955 (2.423 to 0.513) 0.202
* We used the case detection rate as it was reported at the time of the studies; however, this is now being referred to as ‘treatment coverage’. It is expressed as a
proportion to reflect the number of new and relapsed TB cases notified to the WHO divided by the estimated number of incident TB cases in a given year and country.
† Year when the authors reported data that were analysed in each study.
‡ Mean GDP per capita.
§ Statistically significant.
CI¼ confidence interval; TB¼ tuberculosis; SD¼ standard deviation; GDP¼ gross domestic product; HIV¼ human immunodeficiency virus.
Figure 4 Observed vs. predicted estimates for all unit costs using the best fit model. This figure
presents the relationship between observed data points as reported in the studies and the
estimates predicted by the statistical model. The correlation coefficient (r) measures the strength
and direction of a linear relationship.
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settings. It is hoped that these estimates can inform
global, regional and national priority setting exercis-
es, not as a substitute for local, good-quality primary
data, but as informed estimates when local primary
data are not available. These broad estimates can be
updated using the regression proposed once more
primary data are available from large, country-led
data collection exercises.
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R É S U M É
C O N T E X T E : En dépit de la rareté des données relatives
au coût de la tuberculose (TB), un ensemble substantiel
de preuves s’accumule en ce qui concerne le traitement
de la TB pharmacosensible (DS-TB). Dans cette étude,
nous revoyons les coûts unitaires du traitement de la DS-
TB selon la perspective du prestataire de soins. Nous
examinons également les facteurs à l’origine des
variations de coût et extrapolons les coûts unitaires
dans les pays à revenu faible et modéré (LMIC).
M É T H O D E : Nous avons recherché dans la littérature
publiée et parallèle toutes les estimations de coût de la TB
recueillies empiriquement. Nous avons sélectionné un sous
groupe des estimations relatives au traitement de la DS-
TB. Nous avons extrait des informations relatives aux
activités et intrants inclus. Nous avons standardisé les
coûts dans une moyenne par personne-mois, adapté un
modèle de régression multiniveaux et contre validé les
prédictions auniveau des pays. Nous avons alors extrapolé
les estimations relatives au traitement de la DS-TB par
DOTS en structures de santé dans les différents pays.
R É S U LTAT S : Nous avons inclus 95 estimations de 28
études dans 17 pays. Les prédictions de coût ont été
sensibles à des caractéristiques comme le mode de
prestation, l’inclusion d’une hospitalisation, et les
intrants ainsi qu’au produit national brut per capita.
Les résultats de l’extrapolation sont présentés avec une
incertitude pour les LMIC. Les coûts médians prédits
pour six mois de traitement ont été de US$315,30
(US$222,60–US$417,20) pour les pays à revenu faible,
US$527,10 (US$395,70–US$743,70) pour les pays à
revenu moyen faible, et US$896,40 (US$654,00–
US$1214,40) pour les pays à revenu intermédiaire
supérieur.
C O N C L U S I O N : Notre étude fournit des estimations
de coût du traitement de la DS-TB par pays adaptée à
l’établissement de priorités. Ces estimations, qui ne
sont toutefois pas un substitut à des données
primaires locales de grande qualité, peuvent
informer les exercices mondiaux, régionaux et
nationaux.
R E S U M E N
M A R C O D E R E F E R E N C I A: A pesar de la escasez de
datos sobre el costo de la tuberculosis (TB), se ha
acumulado suficiente evidencia en el caso del
tratamiento de la TB sensible a los medicamentos (DS-
TB). En este estudio, revisamos sistemáticament los
costos unitarios para el tratamiento de DS-TB desde la
perspectiva de un proveedor. También examinamos los
factores influyentes en la variación de los costos y
extrapolamos los costos unitarios en los paı́ses de
ingresos bajos y medianos (LMIC).
M É T O D O: Se realizaron búsquedas en la literatura
publicada y no publicada to identificar cualquier
estimación empı́rica de costos de TB. De este group,
seleccionamos un subgrupo de estimaciones que
analizan el tratamiento de DS-TB. Información sobre
actividades e insumos incluidos fue extraida.
Estandarizamos los costos a un promedio por
persona por mes. Ajustamos un modelo de regresión
multinivel a la muestra de costs y validamos las
predicciones a nivel de paı́s. Finalmente, extrapolamos
las estimaciones para el tratamiento directamente
observado de la DS-TB en las facilidades a los paı́ses
restantes.
R E S U LTA D O S: Se incluyeron 95 estimaciones de costos
a partir de 28 estudios en 17 paı́ses. Las predicciones de
costos varian dependiendo de caracterı́sticas como el
tipo de servicio, si el costo de la hospitalización fue
incluida y los insumos incluidos, ası́ como el producto
interno bruto per cápita. Los resultados de
extrapolación se presentan con incertidumbre para los
LMIC. Los costos promedios por seis meses de
tratamiento fueron US$315,30 (US$222,60–
US$417,20) en paı́ses de ingresos bajos, US$527,10
(US$395,70–US$743.70) en paı́ses de ingresos
medianos bajos y US$896,40 (US$654,00–
US$1214,40) en paı́ses de ingresos medianos altos.
C O N C L U S I O N E S: Nuestro estudio presenta estimaciones
de costos de tratamiento de la DS-TB nacionales
adecuadas para establecer prioridades. Estas
estimaciones, aunque no son un sustituto de datos
primaries y locales de alta calidad, pueden informar
ejercicios globales, regionales y nacionales.
TB costs in low- and middle-income countries i
